Prognostic significance of MT1-MMP expression in breast cancer

doi:10.3877/cma.j.issn.1674-0807.2009.01.006

Abstract

Abstract:

Objective

To explore the clinical significance of MT1-MMP expression in breast cancer.

Methods

The MT1-MMP protein expression was detected in human breast cancer specimens from 106 patients by immunohistochemistry assay.Statistical analysis was performed using SPSS 11.0 statistical software. The correlation between MT1-MMP expression and other pathological variables in breast cancer was determined by the Chi-square test and Spearman rank correlation test. The Kaplan-Meier method and the Cox proportional hazard model were used for survival analysis.

Results

The expression of MT1-MMP protein was found in 62.3% of the breast samples.There was a positive correlation between advanced stage or lymph node involvement and MT1-MMP positivity(P＜0.050). No correlation was found between MT1-MMP immunoreactivity and tumor size, HER-2, estrogen or progesterone receptor status. The 7-year disease-free survival was remarkably different between patients with MT1-MMP negative tumors (65.0%) and with MT1-MMP weakly or moderately positive tumors(27.1%) or highly positive tumors (27.8%) (P＜0.050). The 7-year overall survival was significantly different in patients with different MT1-MMP expressions: MT1-MMP( -) was 77.5%; MT1-MMP ( + ～) was 60.4%; and MT1-MMP () was 50.0%, with statistically significant difference (P＜0.050). MT1-MMP positivity correlated significantly with shortened survival in patients with different lymphonode involvement and stage. The mortality rate was different in the patient groups with stage T₂ and T₄, but identical in the patient groups with T₁ and T₃. A multivariate analysis showed that MT1-MMP positivity in cancer cells maintained its association with a poor outcome. The relative risk increased by 1.3 times in the patients with weak or moderate positivity and by 2 times in the patients with highly positive tumors.

Conclusion

The expression of MT1-MMP is correlated with breast cancer aggression and metastasis.MT1-MMP expression in breast cancer is a prognostic factor .

Key words: Membrane type-1 matrix metalloproteinase; Breast neoplasms;Prognosis

Guangyu YAO, Ping HE, Xi WANG, Jun TANG, Rong-cheng LUO, Chang-sheng YE, Jun-ye WANG, Tie-hua RONG, Ming-tian YANG. Prognostic significance of MT1-MMP expression in breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2009, 03(01): 22-31.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2009.01.006

https://zhrxbzz.cma-cmc.com.cn/EN/Y2009/V03/I01/22

Figures/Tables 6

References 10

[1]	Rydlova M, Holubec L Jr,Ludvikova M Jr,et al. Biological activity and clinical implications of the matrix etalloproteinases. Anticancer Res,2008,28:1389 -1397.
[2]	姚广裕,曾木圣,林鹏,等.膜型基质金属蛋白酶-1 对乳腺癌细胞浸润能力的影响.中华肿瘤杂志,2006,28:650 -653.
[3]	柴凡.乳腺癌预后相关分子标记物的研究进展.中华乳腺病杂志:电子版,2007,1:56 -58.
[4]	许良中,杨文涛.免疫组织化学反应结果的判断标准.中国癌症杂志,1996,6:229 -230.
[5]	Goldhirsch A, Wood W C, Gelber R D, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol,2007,18:1133 -1144.
[6]	Ishigaki S, Toi M, Ueno T, et al. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer.Jpn J Cancer Res,1999,90:516 -522.
[7]	Jones J L, Glynn P, Walker R A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol,1999,189:161 -168.
[8]	Kim H J, Park C I, Park B W, et al. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J,2006,47:333 -342.
[9]	Jiang W G, Davies G, Martin T A, et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med,2006,17:583 -590.
[10]	Tetu B, Brisson J, Wang C S, et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res,2006,8:R28.

临床病理因子	例数	MT1-MMP表达[例(%)]			P值
临床病理因子	例数	-	+～		P值
肿瘤大小					0.635^a
T₁	23	11(47.8%)	8(34.8%)	4(17.4%)
T₂	58	23(39.7%)	26(44.8%)	9(15.5%)
T₃	17	5(29.4%)	9(52.9%)	3(17.6%)
T₄	8	1(12.5%)	5(62.5%)	2(25.0%)
淋巴结转移					0.001^a
N₀	37	23(62.2%)	11(29.7%)	3(8.1%)
N₁	46	15(32.6%)	22(47.8%)	9(19.6%)
N₂	23	2(8.7%)	15(65.2%)	6(26.1%)
分期					0.002^a
Ⅰ	9	6(66.7%)	2(22.2%)	1(11.1%)
Ⅱ	72	32(44.4%)	30(41.7%)	10(13.9%)
Ⅲ	25	2(8.0%)	16(64.0%)	7(28.0%)
ER					0.210
-	60	19(31.7%)	28(46.7%)	13(21.7%)
+	46	21(45.7%)	20(43.5%)	5(10.9%)
PR					0.436
-	64	21(32.8%)	31(48.4%)	12(18.8%)
+	42	19(45.2%)	17(40.5%)	6(14.3%)
HER-2					0.758
-	57	20(35.1%)	26(45.6%)	11(19.3%)
+	49	20(40.8%)	22(44.9%)	7(14.3%)

临床病理因子	例数	MT1-MMP表达[例(%)]			P值
临床病理因子	例数	-	+～		P值
肿瘤大小					0.635^a
T₁	23	11(47.8%)	8(34.8%)	4(17.4%)
T₂	58	23(39.7%)	26(44.8%)	9(15.5%)
T₃	17	5(29.4%)	9(52.9%)	3(17.6%)
T₄	8	1(12.5%)	5(62.5%)	2(25.0%)
淋巴结转移					0.001^a
N₀	37	23(62.2%)	11(29.7%)	3(8.1%)
N₁	46	15(32.6%)	22(47.8%)	9(19.6%)
N₂	23	2(8.7%)	15(65.2%)	6(26.1%)
分期					0.002^a
Ⅰ	9	6(66.7%)	2(22.2%)	1(11.1%)
Ⅱ	72	32(44.4%)	30(41.7%)	10(13.9%)
Ⅲ	25	2(8.0%)	16(64.0%)	7(28.0%)
ER					0.210
-	60	19(31.7%)	28(46.7%)	13(21.7%)
+	46	21(45.7%)	20(43.5%)	5(10.9%)
PR					0.436
-	64	21(32.8%)	31(48.4%)	12(18.8%)
+	42	19(45.2%)	17(40.5%)	6(14.3%)
HER-2					0.758
-	57	20(35.1%)	26(45.6%)	11(19.3%)
+	49	20(40.8%)	22(44.9%)	7(14.3%)

临床病理因子	例数	7年生存率			Log Rank检验(P值)
临床病理因子	例数	-	+～		Log Rank检验(P值)
肿瘤大小
T₁	23	9/11(81.8%)	4/8(50.0%)	2/4(50.0%)	0.108
T₂	58	19/23(82.6%)	18/26(69.2%)	4/9(44.4%)	0.035
T₃	17	4/5(80.0%)	8/9(88.9%)	0/3(0.0%)	0.052
T₄	8	1/1(100.0%)	0/5(0.0%)	0/2(0.0%)	0.018
淋巴结转移
N₀	37	21/23(91.3%)	10/11(90.9%)	1/3(33.3%)	0.008
N₁	46	11/15(73.3%)	13/22(59.1%)	4/9(44.4%)	0.028
N₂	23	1/2(50.0%)	7/15(46.7%)	1/6(16.7%)	0.013
分期
Ⅱ	72	26/32(81.3%)	20/30(66.7%)	5/10(50.0%)	0.047
Ⅲ	25	1/2(50.0%)	8/16(50.0%)	1/7(14.3%)	0.038

临床病理因子	例数	7年生存率			Log Rank检验(P值)
临床病理因子	例数	-	+～		Log Rank检验(P值)
肿瘤大小
T₁	23	9/11(81.8%)	4/8(50.0%)	2/4(50.0%)	0.108
T₂	58	19/23(82.6%)	18/26(69.2%)	4/9(44.4%)	0.035
T₃	17	4/5(80.0%)	8/9(88.9%)	0/3(0.0%)	0.052
T₄	8	1/1(100.0%)	0/5(0.0%)	0/2(0.0%)	0.018
淋巴结转移
N₀	37	21/23(91.3%)	10/11(90.9%)	1/3(33.3%)	0.008
N₁	46	11/15(73.3%)	13/22(59.1%)	4/9(44.4%)	0.028
N₂	23	1/2(50.0%)	7/15(46.7%)	1/6(16.7%)	0.013
分期
Ⅱ	72	26/32(81.3%)	20/30(66.7%)	5/10(50.0%)	0.047
Ⅲ	25	1/2(50.0%)	8/16(50.0%)	1/7(14.3%)	0.038

因素	Wald	df	P值	RR
肿瘤大小
T₁	9.41	3	0.02	1.000
T₂	4.551	1	0.03	2.588
T₃	5.406	1	0.02	3.013
T₃	4.106	1	0.04	3.469
淋巴结转移
N₀	11.264	2	0.003	1.000
N₁	7.755	1	0.005	4.141
N₂	10.941	1	0.001	5.171
分期
Ⅰ	13.872	2	0.001	1.000
Ⅱ	9.400	1	0.002	3.680
Ⅲ	11.651	1	0.001	8.077
ER	3.891	1	0.044	2.330
HER-2	1.222	1	0.027	1.616
MT1-MMP
-	6.513	2	0.037	1.000
+～	3.761	1	0.045	2.332
	5.114	1	0.025	3.050

Please choose a citation manager

Content to export